logo-loader
Energy
Parkmead Group

Parkmead posts 70% jump in full-year revenue, gross profit more than trebles

The AIM-listed, UK and Netherlands-focused firm saw its revenue increase to £7.0mln for the year ended 30 June 2018, up from £4.1mln a year earlier

Dial
Parkmead said its gross profit for the period was £4.1mln an increase of 242% on the previous year’s £1.2mln

Parkmead PLC (LON:PMG) shares pushed higher on Friday after the independent energy group reported a 70% jump in full-year revenue and more than trebled its gross profit.

The AIM-listed, UK and Netherlands-focused firm saw its revenue increase to £7.0mln for the year ended 30 June 2018, up from £4.1mln a year earlier.

READ: Parkmead shares rise as it steps-up Greater Perth Area oil hub

The group’s gross profit for the period was £4.1mln an increase of 242% on the previous year’s £1.2mln.

Parkmead highlighted its strong total asset base, which was £78.9mln as at 30 June 2018, and said it remains well capitalised, with cash balances of US$31.0mln (£23.8mln) on the same date.

The company noted that, to date,  it has completed seven acquisitions, at both asset and corporate level, and said it is “actively evaluating further growth opportunities”.

The group executive chairman, Tom Cross, commented: “Parkmead is well positioned for the future. We have excellent UK and Netherlands regional expertise, significant cash resources, and a growing portfolio of assets.

He added: “The Group will continue to build upon the inherent value in its existing interests with a balanced, acquisition-led growth strategy, securing opportunities that maximise long-term value for our shareholders."

In early morning trading, Parkmead shares were 3% higher at 62.00p.

Quick facts: Parkmead Group

Price: £0.42

Market: AIM
Market Cap: £41.75 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan 'driving research for novel drug development for rare diseases'

Proactive London sits down with Open Orphan PLC's (LON:ORPH) chief operating officer Maurice Treacy. Treacy discusses how he became involved with Open Orphan and his ambitions for the firm's health data initiative. ''Many rare diseases aren't known or badly diagnosed ... but rare isn't...

1 hour, 33 minutes ago

2 min read